SCHEMBL1887372

SCHEMBL1887372

CCn1ccc(O)c(C(=O)Nc2nc3ccccc3[nH]2)c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.61
LMNA P02545 3/20 0.61
MAPT P10636 2/20 0.61
S1PR2 O95136 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
USP2 O75604 1/20 0.55
ALOX15 P16050 1/20 0.55
RAB9A P51151 9/20 0.54
NPC1 O15118 8/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
XBP1 P17861 1/20 0.54
PKM P14618 3/20 0.53
KLF5 Q13887 2/20 0.53
SMN1; SMN2 Q16637 5/20 0.52
ALDH1A1 P00352 3/20 0.52
MAOB P27338 1/20 0.51
ADORA2A P29274 1/20 0.51
RECQL P46063 1/20 0.51
OPRK1 P41145 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12417667 0.89 LMNA (0.54) HTTLMNAMAPTS1PR2NPSR1
SCHEMBL1892848 0.86 RAB9A (0.58) HTTLMNAMAPTS1PR2NPSR1
SCHEMBL14297040 0.86 HTT (0.56) HTTLMNAMAPTS1PR2NPSR1
SCHEMBL1890286 0.78 RAB9A (0.57) HTTLMNAMAPTS1PR2NPSR1
SCHEMBL2191224 0.76 HTT (0.41) HTTLMNAMAPTS1PR2NPSR1
SCHEMBL1889444 0.76 IRAK4 (0.42) HTTLMNAMAPTS1PR2NPSR1
SCHEMBL1884510 0.72 IRAK4 (0.48) HTTLMNAMAPTS1PR2NPSR1
SCHEMBL1884504 0.72 RAB9A (0.45) HTTLMNAMAPTS1PR2NPSR1
SCHEMBL12417674 0.72 RAB9A (0.51) HTTLMNAMAPTS1PR2NPSR1
SCHEMBL12417619 0.71 BRD4 (0.38) HTTNPSR1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1887002-B1 CARBOXAMIDE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2015-08-26 EP disclosed
US-8304437-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-06 US disclosed
US-8304437-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-06 US disclosed
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME ARIMORI SADAYUKI 2011-07-14 US disclosed
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME ARIMORI SADAYUKI 2011-07-14 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
EP-1887002-A1 CARBOXAMIDE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076063-A1 Carboxamide compound and use of the same CBR3, SIRT2, SIRT1 HTT 1488/4885LMNA 1426/4885MAPT 3161/4885
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME CBR3, SIRT2, SIRT1 HTT 1488/4885LMNA 1426/4885MAPT 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.